Ballantyne Therapeutics, Inc. — Form D/A
Ballantyne Therapeutics, Inc. of CHARLOTTE, NC, a company, filed a Form D amendment with the SEC on 2015-10-22. The offering totals $800K, of which $565K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2015-10-22
- Form: D/A
- Accession: 0001586429-15-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $800K
- Amount sold: $565K
- Remaining: $235K
- Investors: 8
- Date of first sale: 2015-05-08
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-243626
Issuer
- Name: Ballantyne Therapeutics, Inc.
- CIK: 0001645966
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 13850 Ballantyne Corporate Place, CHARLOTTE, NC, 28277
- Phone: 704-887-3422
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Brian E Doxtator | Director | Charlotte, NC |
| Simon Pedder | Director | Charlotte, NC |
| Donald R Reynolds | Director | Charlotte, NC |
| Michael Roberts | Director | Roswell, GA |
| Michael Roberts | Executive Officer | Roswell, GA |
Other filings by this issuer (1)
More